War on Ebola—knowledge is power in the fight to control epidemics

November 11, 2016 by Mary Cruse, Oxford Science Blog, University of Oxford
The recent Ebola epidemic can be traced to a forest in southern Guinea. Credit: Oxford Science Blog

It was a December day like any other in the village of Meliandou: a remote outcrop in the densely forested region of southern Guinea. A young boy named Emile Ouamouno was playing by a tree filled with fruit bats.

Within weeks, the 18-month-old would be dead, along with his mother, sister and grandmother. Now identified as patient zero, Emile likely came into contact with infected , becoming the first victim of the most deadly Ebola epidemic in history.

From Meliandou, the virus spread to the surrounding towns and cities, sweeping through friends, families and healthcare workers. By the time it was recognised as Ebola by the World Health Organisation, the virus had already spread through Guinea and would soon cross the border into Liberia and Sierra Leone.

From West Africa, Ebola travelled around the world – the UK, France, Spain and America were all affected by the deadly spread. And over the course of the next two years, more than 11,300 people would die as a result.

In early-2016, the WHO officially declared the Ebola emergency over. But there's no question that Ebola and other pathogens like it will emerge again.

In an increasingly connected world, the need to develop a frontline defence against viral epidemics is greater now than ever. And while there are many factors at play in successfully managing an outbreak, one of the greatest weapons we have is knowledge.

The way that viruses function is closely linked to their structure on the atomic level. Like most organisms, viruses contain complex molecular machinery that allows them to survive and thrive. By unpicking the atomic structure of viruses, we can identify vulnerabilities and create medicines that exploit these weaknesses to counteract infection.

Ebola has been around for a long time, but we've not yet developed either a working vaccine or a treatment to counteract the disease. This is partly because no outbreak has ever before been so widespread or so deadly. It's also because Ebola's intricate structure makes it a very tricky virus to treat.

Ebola is what's known as an 'enveloped' virus, meaning that it is surrounded by a protective membrane which contains proteins that allow it to latch on to host cells. These 'glycoproteins' make Ebola strong, but they also make it vulnerable.

Glycoproteins are important to Ebola's spread, so they're an obvious target for medical interventions. A vaccine currently in clinical trials induces immunity in patients by exposing them to small samples of the virus's glycoproteins.

Research from Diamond Light Source's crystallography beamlines suggests a similar approach could be used to develop antivirals. Led by Professor Dave Stuart, scientists from Oxford University have recently used synchrotron light to produce atomic-scale images of the cancer drug Toremifene and the painkiller Ibuprofen, bound to Ebola glycoproteins, thus preventing viral fusion.

The two common drugs appear to latch on to a small pocket in the structure of the glycoproteins, where they trick the Ebola cell into thinking it's attached itself to a host cell. The virus then begins releasing genetic information, but without a host cell viral spread looks to be disabled, and eventually the virus population withers.

This is a major step forward: we now have compounds that can inhibit the spread of Ebola. What's more, we know how they do it in atomic detail.

On their own, these drugs aren't enough to curtail infection, but now that we know exactly how they interact with the virus, it should be possible to improve the compounds so that they bind more tightly to Ebola and stop the virus in its tracks.

The Ebola crisis in West Africa centred the world's attention on the devastating consequences of viral epidemics. Three years on from the beginning of the outbreak and international health experts have learned some valuable lessons about the structure underlying the deadly , enhancing our ability to shield ourselves from attack.

These steps forward won't be enough to help those affected by the latest tragedy, but they demonstrate more than ever that basic research is the route to effective clinical impact.

We know that we need to act quickly to stamp out epidemics, and when it comes to fighting viruses, knowledge is power. That's why the ability to study pathogens like Ebola on the atomic level is so important.

Because, if we look closely enough, we might find an Achilles' heel, a chink in the armour, a way to fight back.

Explore further: UN: Latest Ebola outbreak in Guinea is now over

Related Stories

UN: Latest Ebola outbreak in Guinea is now over

June 1, 2016
The World Health Organization says the latest Ebola outbreak in Guinea has ended and the country is now entering a 90-day heightened surveillance period to monitor for any unexpected cases.

WHO revises Ebola toll

November 1, 2014
The World Health Organization Friday revised its figures showing more people killed by the deadly Ebola virus, but the number of cases of the disease was slightly lower.

Liberia's last known Ebola patients discharged from hospital

May 4, 2016
Liberia's last two known Ebola patients have been discharged from hospital after recovering from the disease, the ministry of health said Wednesday.

Sierra Leone Ebola head says country has four cases

August 6, 2015
Sierra Leone has only four recorded cases of Ebola, the West African nation's head of Ebola said Thursday, adding that he is hopeful the countdown to zero can soon begin.

Sierra Leone on alert after new W.Africa Ebola cases

April 10, 2016
Sierra Leone called Sunday for increased vigilance to prevent a resurgence of the Ebola virus after new cases in neighbouring Liberia and Guinea, but cautioned against shutting off borders between the west African states.

Recommended for you

Researchers seek vaccine for 'traveler's diarrhea'

September 25, 2018
Every year, millions of people have vacations and business trips ruined when they succumb to "traveler's diarrhea" during their journeys. A major cause of traveler's diarrhea is bacteria called Enterotoxigenic E. coli, or ...

Experimental vaccine shows promise in preventing TB

September 25, 2018
(HealthDay)—Tuberculosis remains the most lethal of infectious diseases worldwide, killing more than 1.6 million people a year. But researchers say a new vaccine might prevent half of full-blown illnesses in infected people ...

Many doctors in India miss TB signs: study

September 25, 2018
Many private sector doctors in India miss the signs of tuberculosis and therefore provide patients inadequate treatment, according to a new study published Tuesday involving people hired to act out the symptoms.

New way of determining treatment for staph infections cuts antibiotic use

September 25, 2018
Using a clinical checklist to identify eligible patients, doctors were able to shorten the antibiotic duration for patients with uncomplicated staphylococcal bloodstream infections by nearly two days, Duke Health researchers ...

Breakthrough in designing a better Salmonella vaccine

September 24, 2018
UC Davis researchers announce in the Proceedings of the National Academy of Sciences this week a breakthrough in understanding which cells afford optimal protection against Salmonella infection—a critical step in developing ...

Antifungal agent found to be possible treatment for porphyria

September 24, 2018
A large team of researchers from Spain, France and the U.S. has found that a common antifungal agent might be useful as a treatment for a rare type of porphyria. In their paper published in the journal Science Translational ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.